Almirall Views Vitiligo As Next Dermatology Opportunity
Links Up With French Skin Specialist
Executive Summary
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.
You may also be interested in...
Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval
The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”
Clinuvel Plots Competition To Incyte In Vitiligo Space
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.